AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF NIVOLUMAB, OR NIVOLUMAB PLUS IPILIMUMAB, VERSUS PLATINUM DOUBLET CHEMOTHERAPY IN SUBJECTS WITH CHEMOTHERAPY-NAÏVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC)

BRISTOL MYERS SQUIBB COMPANY,0 个研究点目标入组 5 人开始时间: 2016年3月16日最近更新: 2024年8月20日

适应症

试验速览

暂无简介。

•ECOG Performance Status of 1.
•Patients with histologically confirmed Stage IV or recurrent NSCLC (per the 7th International Association for the Study of Lung Cancer classification squamous or nonsquamous histology, with no prior systemic anticancer therapy (including EGFR and ALK inhibitors) given as primary therapy for advanced or metastatic disease.
•Measurable disease by CT or MRI per RECIST 1.1 criteria.

•Subjects with known EGFR mutations which are sensitive to available targeted inhibitor therapy.
•Subjects with known ALK translocations which are sensitive to available targeted inhibitor therapy.
•Subjects with untreated CNS metastases are excluded, even if asymptomatic.
•Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not
•requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are
•permitted to enroll.
•Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topicalsteroids, and adrenal replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.

发起方